Wilson Rebecca L, Hruby Dennis E
SIGA Technologies, Inc., 4575 SW Research Way, Suite 230, Corvallis, OR 97333, USA.
Adv Drug Deliv Rev. 2005 Jun 17;57(9):1392-402. doi: 10.1016/j.addr.2005.01.015. Epub 2005 Apr 14.
Following the anthrax attacks of 2001 and the recent SARS outbreak, concerns about emerging and re-emerging infectious diseases have catalyzed a renewed interest in developing new vaccination strategies that provide rapid and flexible response options to future threats. Because the probability of encountering one of these exotic agents is unknown, it is essential that new vaccine formulations employ methods that provide effective protection and extremely good safety profiles if they are to be used by either military or civilian populations. One approach, which potentially satisfies these criteria, is the use of live recombinant Gram-positive commensal bacteria as expression vectors. This review provides an overview of the system, its advantages and limitations, and details an example of how Gram-positive commensal bacteria are being developed as a fifth generation vaccine against a Class A biowarfare pathogen, namely smallpox.
在2001年炭疽袭击事件和近期非典疫情爆发之后，对新出现和重新出现的传染病的担忧促使人们重新关注开发新的疫苗接种策略，以便对未来的威胁提供快速灵活的应对方案。由于遭遇这些外来病原体之一的可能性未知，因此，如果新的疫苗制剂要供军队或平民使用，至关重要的是采用能提供有效保护且具有极佳安全性的方法。一种可能满足这些标准的方法是使用活的重组革兰氏阳性共生菌作为表达载体。本综述概述了该系统、其优点和局限性，并详细介绍了革兰氏阳性共生菌如何被开发成针对A类生物战病原体天花的第五代疫苗的实例。
